{"title":"以欧米克隆波后15天为基线,托莱多(西班牙)一家全科医院Covid-19感染的特点和疫苗强化效果","authors":"J. Luis Turabián","doi":"10.31579/2639-4162/050","DOIUrl":null,"url":null,"abstract":"Background: Vaccine covid-19 booster effectiveness (VBE) timing is not clearly known Objective: To compare the cases of covid-19 in vaccinated booster people with a time of <15 days vs. >= 15 days from booster to infection diagnosis and assess their relative VBE. Methodology: An observational, longitudinal and prospective study of adult patients with covid-19 breakthrough infections in booster vaccinated people, in general medicine and for the period December 2021 to February 2022, during the omicron variant contagion wave. Results: Forty-six cases were included, 15 cases of Covid-19 breakthrough infections with booster shot <15 days (33%) with a mean time in days from booster to diagnostic covid-19 of 6 days, and 31 cases with booster > = 15 days (67%) with a time in days from booster to covid-19 diagnostic of 37 days of mean. Relative VBE <15 days (cases where it can be considered that the booster is not yet effective) vs. > = 15 days (cases where it can be considered that the booster is already effective) [1 - (Cases with vaccine Booster shot < 15 days) / (Cases with vaccine Booster shot > = 15 days) x 100] was 60%. Covid-19 cases with booster shot <15 days had been more vaccinated with 2 doses of ChAdOx1 nCoV-19 vaccine (Vaxzevria, Oxford / AstraZeneca) plus booster of mRNA-1273 vaccine (Spikevax, formerly covid-19 Vaccine Moderna). Conclusion: In the general practice setting in Toledo, Spain, from December 1, 2021 to February 28, 2022, at the peak of omicron infections, booster after a period of <15 days provided 60% relative protection against symptomatic disease vs. > = 15 days. The results suggest that booster received <15 days provided early protection against SARS-CoV-2 infection of symptomatic Covid-19 of 60%. However, this result does not seem logical: this lower early risk may be transient and due to “vaccinated bias.”","PeriodicalId":93288,"journal":{"name":"General medicine and clinical practice","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characteristics and Vaccine Booster Effectiveness in Covid-19 Infections Using 15 Days Post-Booster Period as Baseline during the Omicron Wave in A General Medicine office in Toledo (Spain)\",\"authors\":\"J. Luis Turabián\",\"doi\":\"10.31579/2639-4162/050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Vaccine covid-19 booster effectiveness (VBE) timing is not clearly known Objective: To compare the cases of covid-19 in vaccinated booster people with a time of <15 days vs. >= 15 days from booster to infection diagnosis and assess their relative VBE. Methodology: An observational, longitudinal and prospective study of adult patients with covid-19 breakthrough infections in booster vaccinated people, in general medicine and for the period December 2021 to February 2022, during the omicron variant contagion wave. Results: Forty-six cases were included, 15 cases of Covid-19 breakthrough infections with booster shot <15 days (33%) with a mean time in days from booster to diagnostic covid-19 of 6 days, and 31 cases with booster > = 15 days (67%) with a time in days from booster to covid-19 diagnostic of 37 days of mean. Relative VBE <15 days (cases where it can be considered that the booster is not yet effective) vs. > = 15 days (cases where it can be considered that the booster is already effective) [1 - (Cases with vaccine Booster shot < 15 days) / (Cases with vaccine Booster shot > = 15 days) x 100] was 60%. Covid-19 cases with booster shot <15 days had been more vaccinated with 2 doses of ChAdOx1 nCoV-19 vaccine (Vaxzevria, Oxford / AstraZeneca) plus booster of mRNA-1273 vaccine (Spikevax, formerly covid-19 Vaccine Moderna). Conclusion: In the general practice setting in Toledo, Spain, from December 1, 2021 to February 28, 2022, at the peak of omicron infections, booster after a period of <15 days provided 60% relative protection against symptomatic disease vs. > = 15 days. The results suggest that booster received <15 days provided early protection against SARS-CoV-2 infection of symptomatic Covid-19 of 60%. However, this result does not seem logical: this lower early risk may be transient and due to “vaccinated bias.”\",\"PeriodicalId\":93288,\"journal\":{\"name\":\"General medicine and clinical practice\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"General medicine and clinical practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31579/2639-4162/050\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"General medicine and clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2639-4162/050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Characteristics and Vaccine Booster Effectiveness in Covid-19 Infections Using 15 Days Post-Booster Period as Baseline during the Omicron Wave in A General Medicine office in Toledo (Spain)
Background: Vaccine covid-19 booster effectiveness (VBE) timing is not clearly known Objective: To compare the cases of covid-19 in vaccinated booster people with a time of <15 days vs. >= 15 days from booster to infection diagnosis and assess their relative VBE. Methodology: An observational, longitudinal and prospective study of adult patients with covid-19 breakthrough infections in booster vaccinated people, in general medicine and for the period December 2021 to February 2022, during the omicron variant contagion wave. Results: Forty-six cases were included, 15 cases of Covid-19 breakthrough infections with booster shot <15 days (33%) with a mean time in days from booster to diagnostic covid-19 of 6 days, and 31 cases with booster > = 15 days (67%) with a time in days from booster to covid-19 diagnostic of 37 days of mean. Relative VBE <15 days (cases where it can be considered that the booster is not yet effective) vs. > = 15 days (cases where it can be considered that the booster is already effective) [1 - (Cases with vaccine Booster shot < 15 days) / (Cases with vaccine Booster shot > = 15 days) x 100] was 60%. Covid-19 cases with booster shot <15 days had been more vaccinated with 2 doses of ChAdOx1 nCoV-19 vaccine (Vaxzevria, Oxford / AstraZeneca) plus booster of mRNA-1273 vaccine (Spikevax, formerly covid-19 Vaccine Moderna). Conclusion: In the general practice setting in Toledo, Spain, from December 1, 2021 to February 28, 2022, at the peak of omicron infections, booster after a period of <15 days provided 60% relative protection against symptomatic disease vs. > = 15 days. The results suggest that booster received <15 days provided early protection against SARS-CoV-2 infection of symptomatic Covid-19 of 60%. However, this result does not seem logical: this lower early risk may be transient and due to “vaccinated bias.”